www.hiv-druginter	actions.org		UNIVERSITY OF LIVERPOOL
		Interaction Report	
Report ID: Date Produced:	06 June 2025		
Antiretroviral Treatment		Co-medications	

Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

Erythromycin

For full details of all interactions, see www.hiv-druginteractions.org .

## Description of the interactions

No clinically significant interaction expected (GREEN)

Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) + Erythromycin

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

s report is provided for information or inicians must exercise their own judg the University of Liverpool harmless currency of info et elleste al heteroeting enclosed, and el based or reinvend data in the public domain. No clinical advice is given or imp et elleste al heteroeting enclosed and include the elleste and elleste and elleste and elleste and elleste and the enclosed of Lengend and include heteroeting enclosed and elleste and elleste and elleste and the user shall hever, the University of Liverpool and its servants or agents shall not be responsible for the continue expressly exclude statistify for encros, missions or inaccuracies to the fulface start permitted by faixe. ended to replace a consultation with an appropriately qualified health professional. Info on to the risks and benefits of combining drugs, which depend on factors beyond pharm resourcence arising form the same. We aim to persure that information is accurate and relates only to known or suspecte ions between two drugs. The Uni